Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosgemcitabine palabenamide - Cardiff University/NuCana Biomed

Drug Profile

Fosgemcitabine palabenamide - Cardiff University/NuCana Biomed

Alternative Names: Acelarin®; CPF-31; Gemcitabine analog - Nucana; Gemcitabine-phosphoramidate; Gemcitabine-ProTide; MTL-007; NUC 1031

Latest Information Update: 11 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics; Pyrimidine nucleosides
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer; Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • No development reported Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 02 Mar 2022 NuCana terminates the phase-III NuTide:121 trial in Biliary cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) Hungary, Spain, France, Czech Republic, Germany, Canada, Australia, South Korea, Taiwan, Turkey, Ukraine, the US, the UK, Italy and Russia (IV) (NCT04163900)
  • 16 Sep 2021 Efficacy data form ABC-08 trial in Biliary cancer presented at the 46th European Society for Medical Oncology Congress (ESMO-2021)
  • 28 Jul 2020 No recent reports of development identified for preclinical development in Bladder-cancer(Combination therapy, First-line therapy) in United Kingdom (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top